Michela Frisinghelli
Overview
Explore the profile of Michela Frisinghelli including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
56
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Merz V, Maines F, Marcucci S, Sartori C, Frisinghelli M, Trentin C, et al.
J Cancer Res Clin Oncol
. 2024 Jul;
150(7):347.
PMID: 38990367
Background: Therapeutic approach used for pancreatic ductal adenocarcinoma is usually translated also for the rarer acinar counterpart, which shows a different mutational landscape nevertheless. While dMMR/MSI-H status is rare in...
2.
Rubatto M, Fava P, Stanganelli I, Ribero S, Pigozzo J, Di Giacomo A, et al.
Eur J Cancer
. 2023 Apr;
187:25-35.
PMID: 37099946
Background: Immunotherapy has improved the survival of patients with stage IV melanoma. In responders, clinical benefits may be long-lasting and persist even after treatment discontinuation. The optimal duration of anti-PD1...
3.
Merz V, Mangiameli D, Zecchetto C, Quinzii A, Pietrobono S, Messina C, et al.
Front Surg
. 2022 May;
9:866173.
PMID: 35599791
The mainstay treatment for patients with immediate resectable pancreatic cancer remains upfront surgery, which represents the only potentially curative strategy. Nevertheless, the majority of patients surgically resected for pancreatic cancer...
4.
Dionisi F, Brolese A, Siniscalchi B, Giacomelli I, Fracchiolla F, Righetto R, et al.
Tumori
. 2020 Jul;
107(1):71-79.
PMID: 32648818
Background: Evidence for the efficacy of radiation therapy for primary liver cancer is growing. In this context, proton therapy (PT) can potentially improve the therapeutic ratio, as demonstrated by recent...
5.
Messina C, Merz V, Frisinghelli M, Trentin C, Grego E, Veccia A, et al.
Crit Rev Oncol Hematol
. 2019 Sep;
143:124-129.
PMID: 31563828
Background: The role of adjuvant chemotherapy (ACT) for resected biliary tract cancer (BTC) is still unclear and there is no specific recommendation by international guidelines. Aim: To perform a meta-analysis...
6.
Dipasquale M, Murgia V, Veccia A, Brugnara S, Caldara A, Ferro A, et al.
Anticancer Drugs
. 2017 Mar;
28(6):654-659.
PMID: 28252532
To assess the activity of weekly paclitaxel (wPCT) in pretreated patients with advanced non-small-cell lung cancer (aNSCLC). In 2005, we included wPCT 80 mg/m for 6 consecutive weeks, followed by...
7.
Caffo O, Pappagallo G, Brugnara S, Caldara A, di Pasquale M, Ferro A, et al.
Urology
. 2012 Mar;
79(3):644-9.
PMID: 22386418
Objective: To describe the feasibility and efficacy of multiple sequential rechallenges and analyze the predictive factors that may aid in selecting patients who are more likely to respond. Several studies...
8.
Caffo O, Fellin G, Bolner A, Coccarelli F, Divan C, Frisinghelli M, et al.
Int J Radiat Oncol Biol Phys
. 2006 Jun;
66(1):31-7.
PMID: 16765529
Purpose: Permanent interstitial brachytherapy (IB) has become an increasingly appealing therapeutic option for localized prostate cancer (LPC) among physicians and patients because it involves short hospitalization and treatment and its...
9.
Molino A, Pedersini R, Micciolo R, Frisinghelli M, Giovannini M, Pavarana M, et al.
Appl Immunohistochem Mol Morphol
. 2003 Dec;
11(4):311-8.
PMID: 14663356
Laminin is a basement membrane glycoprotein implicated in a large number of biologic activities of cancer progression, many of which are mediated by the presence of the laminin receptor (67LR)...
10.
Molino A, Pedersini R, Micciolo R, Frisinghelli M, Giovannini M, Pavarana M, et al.
Appl Immunohistochem Mol Morphol
. 2003 Feb;
10(4):304-9.
PMID: 12607597
Proliferative activity has been proposed as a prognostic and predictive marker for breast cancer; Ki-67 is one of the most frequently used markers to assess proliferative activity. In the current...